CD19 and myeloid leukemia: The transmembrane glycoprotein CD19 (95 kDa) and the early myelopoietic antigen CD33 (approximately 67–75 kDa), seemed to be suitable and prominent surface markers to distinguish myelogenous leukemia cells from lymphoid or erythroid leukemia and were also clinically validated antigens for development of antibody-based immunotherapeutic (bi- or tri-specific) construct’s (47–49).